vs

Side-by-side financial comparison of Core Laboratories Inc. (CLB) and HACKETT GROUP, INC. (HCKT). Click either name above to swap in a different company.

Core Laboratories Inc. is the larger business by last-quarter revenue ($121.8M vs $68.8M, roughly 1.8× HACKETT GROUP, INC.). HACKETT GROUP, INC. runs the higher net margin — 6.2% vs 4.2%, a 2.0% gap on every dollar of revenue. On growth, Core Laboratories Inc. posted the faster year-over-year revenue change (-1.4% vs -11.6%). Over the past eight quarters, Core Laboratories Inc.'s revenue compounded faster (-3.4% CAGR vs -5.9%).

Abbott Laboratories, commonly known as Abbott, is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois. The company produces pharmaceuticals for sale outside the United States, diagnostic products, nutritional products, and medical devices.

Hackett Limited is a British multi-channel retailer of clothing for men and boys, with a broad range of apparel and accessories. It was founded in 1983 in London, England. As of June 2019, the company had 160 stores globally, with its flagship store at 14 Savile Row in London. It is owned by both Lebanese holding company M1 Group and American L Capital Asia

CLB vs HCKT — Head-to-Head

Bigger by revenue
CLB
CLB
1.8× larger
CLB
$121.8M
$68.8M
HCKT
Growing faster (revenue YoY)
CLB
CLB
+10.2% gap
CLB
-1.4%
-11.6%
HCKT
Higher net margin
HCKT
HCKT
2.0% more per $
HCKT
6.2%
4.2%
CLB
Faster 2-yr revenue CAGR
CLB
CLB
Annualised
CLB
-3.4%
-5.9%
HCKT

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
CLB
CLB
HCKT
HCKT
Revenue
$121.8M
$68.8M
Net Profit
$5.1M
$4.3M
Gross Margin
70.8%
Operating Margin
1.5%
13.0%
Net Margin
4.2%
6.2%
Revenue YoY
-1.4%
-11.6%
Net Profit YoY
36.2%
EPS (diluted)
$0.11
$0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLB
CLB
HCKT
HCKT
Q1 26
$121.8M
$68.8M
Q4 25
$138.3M
$75.8M
Q3 25
$134.5M
$73.1M
Q2 25
$130.2M
$78.9M
Q1 25
$123.6M
$77.9M
Q4 24
$129.2M
$79.2M
Q3 24
$134.4M
$79.8M
Q2 24
$130.6M
$77.7M
Net Profit
CLB
CLB
HCKT
HCKT
Q1 26
$5.1M
$4.3M
Q4 25
$4.9M
$5.6M
Q3 25
$14.2M
$2.5M
Q2 25
$10.6M
$1.7M
Q1 25
$-154.0K
$3.1M
Q4 24
$7.4M
$3.6M
Q3 24
$11.7M
$8.6M
Q2 24
$9.0M
$8.7M
Gross Margin
CLB
CLB
HCKT
HCKT
Q1 26
70.8%
Q4 25
20.8%
41.7%
Q3 25
22.0%
40.7%
Q2 25
20.3%
35.4%
Q1 25
19.5%
35.8%
Q4 24
17.8%
39.4%
Q3 24
20.5%
29.2%
Q2 24
21.2%
27.5%
Operating Margin
CLB
CLB
HCKT
HCKT
Q1 26
1.5%
13.0%
Q4 25
11.5%
12.0%
Q3 25
15.6%
7.5%
Q2 25
11.7%
5.8%
Q1 25
3.6%
5.7%
Q4 24
11.0%
9.8%
Q3 24
14.7%
16.0%
Q2 24
12.3%
16.1%
Net Margin
CLB
CLB
HCKT
HCKT
Q1 26
4.2%
6.2%
Q4 25
3.6%
7.4%
Q3 25
10.6%
3.5%
Q2 25
8.2%
2.1%
Q1 25
-0.1%
4.0%
Q4 24
5.7%
4.5%
Q3 24
8.7%
10.8%
Q2 24
6.9%
11.3%
EPS (diluted)
CLB
CLB
HCKT
HCKT
Q1 26
$0.11
$0.17
Q4 25
$0.11
$0.20
Q3 25
$0.30
$0.09
Q2 25
$0.22
$0.06
Q1 25
$0.00
$0.11
Q4 24
$0.15
$0.11
Q3 24
$0.25
$0.31
Q2 24
$0.19
$0.31

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLB
CLB
HCKT
HCKT
Cash + ST InvestmentsLiquidity on hand
$22.8M
Total DebtLower is stronger
$78.8M
Stockholders' EquityBook value
$275.1M
$66.0M
Total Assets
$587.7M
$204.4M
Debt / EquityLower = less leverage
1.19×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLB
CLB
HCKT
HCKT
Q1 26
$22.8M
Q4 25
$22.7M
$18.2M
Q3 25
$25.6M
$13.9M
Q2 25
$31.2M
$10.1M
Q1 25
$22.1M
$9.2M
Q4 24
$19.2M
$16.4M
Q3 24
$21.5M
$10.0M
Q2 24
$17.7M
$19.1M
Total Debt
CLB
CLB
HCKT
HCKT
Q1 26
$78.8M
Q4 25
$110.3M
Q3 25
$114.1M
Q2 25
$124.6M
Q1 25
$124.4M
Q4 24
$126.1M
Q3 24
$139.9M
Q2 24
$147.6M
Stockholders' Equity
CLB
CLB
HCKT
HCKT
Q1 26
$275.1M
$66.0M
Q4 25
$266.0M
$68.1M
Q3 25
$271.3M
$101.6M
Q2 25
$261.3M
$119.8M
Q1 25
$253.4M
$114.4M
Q4 24
$246.6M
$115.6M
Q3 24
$250.7M
$110.9M
Q2 24
$240.3M
$102.2M
Total Assets
CLB
CLB
HCKT
HCKT
Q1 26
$587.7M
$204.4M
Q4 25
$584.0M
$206.4M
Q3 25
$591.4M
$200.7M
Q2 25
$602.1M
$200.5M
Q1 25
$591.5M
$191.8M
Q4 24
$585.1M
$193.3M
Q3 24
$600.5M
$190.8M
Q2 24
$597.8M
$187.5M
Debt / Equity
CLB
CLB
HCKT
HCKT
Q1 26
1.19×
Q4 25
0.41×
Q3 25
0.42×
Q2 25
0.48×
Q1 25
0.49×
Q4 24
0.51×
Q3 24
0.56×
Q2 24
0.61×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLB
CLB
HCKT
HCKT
Operating Cash FlowLast quarter
$4.0M
Free Cash FlowOCF − Capex
$517.0K
FCF MarginFCF / Revenue
0.4%
Capex IntensityCapex / Revenue
3.5%
Cash ConversionOCF / Net Profit
0.77×
TTM Free Cash FlowTrailing 4 quarters
$22.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLB
CLB
HCKT
HCKT
Q1 26
$4.0M
Q4 25
$7.9M
$19.1M
Q3 25
$8.5M
$11.4M
Q2 25
$13.9M
$5.6M
Q1 25
$6.7M
$4.2M
Q4 24
$20.6M
$20.6M
Q3 24
$13.1M
$10.6M
Q2 24
$17.1M
$13.7M
Free Cash Flow
CLB
CLB
HCKT
HCKT
Q1 26
$517.0K
Q4 25
$5.0M
Q3 25
$6.5M
Q2 25
$10.4M
$3.7M
Q1 25
$3.9M
$2.6M
Q4 24
$17.4M
$19.6M
Q3 24
$10.4M
$9.3M
Q2 24
$14.3M
$12.8M
FCF Margin
CLB
CLB
HCKT
HCKT
Q1 26
0.4%
Q4 25
3.6%
Q3 25
4.8%
Q2 25
8.0%
4.7%
Q1 25
3.1%
3.4%
Q4 24
13.4%
24.8%
Q3 24
7.7%
11.7%
Q2 24
10.9%
16.5%
Capex Intensity
CLB
CLB
HCKT
HCKT
Q1 26
3.5%
Q4 25
2.1%
Q3 25
1.5%
Q2 25
2.7%
2.4%
Q1 25
2.3%
2.0%
Q4 24
2.5%
1.3%
Q3 24
2.0%
1.5%
Q2 24
2.2%
1.1%
Cash Conversion
CLB
CLB
HCKT
HCKT
Q1 26
0.77×
Q4 25
1.61×
3.41×
Q3 25
0.60×
4.47×
Q2 25
1.31×
3.40×
Q1 25
1.33×
Q4 24
2.78×
5.79×
Q3 24
1.12×
1.23×
Q2 24
1.90×
1.57×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLB
CLB

Segment breakdown not available.

HCKT
HCKT

Revenue before reimbursements$36.4M53%
Other$32.0M47%
Reimbursements$405.0K1%

Related Comparisons